Publicacións en colaboración con investigadores/as de Hospital de Cabueñes (26)

2024

  1. Psoriasis induced by antiTNF therapy in inflammatory bowel disease: Therapeutic management and evolution of both diseases in a nationwide cohort study

    Digestive and Liver Disease, Vol. 56, Núm. 12, pp. 2060-2068

  2. Types, behaviour and therapeutic requirements of inflammatory pouch disorders: Results from the RESERVO study of GETECCU

    Digestive and Liver Disease

2023

  1. Long-Term Outcomes of Biological Therapy in Crohn's Disease Complicated with Internal Fistulizing Disease: BIOSCOPE Study from GETECCU

    American Journal of Gastroenterology, Vol. 118, Núm. 6, pp. 1036-1046

  2. The Risk of Developing Disabling Crohn's Disease: Validation of a Clinical Prediction Rule to Improve Treatment Decision Making

    Digestive Diseases, Vol. 41, Núm. 6, pp. 879-889

2022

  1. Correction: Chaparro et al. Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study (J. Clin. Med., (2021), 10, (2885), 10.3390/jcm10132885)

    Journal of Clinical Medicine

  2. Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native Patients

    Frontiers in Medicine, Vol. 9

  3. Psychosocial impact of the COVID-19 pandemic on patients with inflammatory bowel disease in Spain. A post lockdown reflection

    Gastroenterologia y Hepatologia, Vol. 45, Núm. 9, pp. 668-676

  4. Surgery due to Inflammatory Bowel Disease During Pregnancy: Mothers and Offspring Outcomes From an ECCO Confer Multicentre Case Series [Scar Study

    Journal of Crohn's & colitis, Vol. 16, Núm. 9, pp. 1428-1435

2021

  1. Incidence, clinical characteristics and management of inflammatory bowel disease in spain: Large-scale epidemiological study

    Journal of Clinical Medicine, Vol. 10, Núm. 13

2019

  1. Genetic association between CD96 locus and immunogenicity to anti-TNF therapy in Crohn’s disease

    Pharmacogenomics Journal, Vol. 19, Núm. 6, pp. 547-555

2018

  1. Serial tuberculin skin tests improve the detection of latent tuberculosis infection in patients with inflammatory bowel disease

    Journal of Crohn's and Colitis, Vol. 12, Núm. 11, pp. 1270-1279

2017

  1. Adalimumab Maintenance Treatment in Ulcerative Colitis: Outcomes by Prior Anti-TNF Use and Efficacy of Dose Escalation

    Digestive Diseases and Sciences, Vol. 62, Núm. 2, pp. 481-490

  2. Early tuberculin skin test for the diagnosis of latent tuberculosis infection in patients with inflammatory Bowel disease

    Journal of Crohn's and Colitis, Vol. 11, Núm. 7, pp. 792-800

  3. Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ± ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection

    Journal of Viral Hepatitis, Vol. 24, Núm. 3, pp. 226-237

  4. The ART-SCORE is not an effective tool for optimizing patient selection for DEB-TACE retreatment. A multicentre Spanish study

    Gastroenterologia y Hepatologia, Vol. 40, Núm. 8, pp. 515-524

2016

  1. Outcomes of medical and surgical therapy for entero-urinary fistulas in Crohn's disease

    Journal of Crohn's and Colitis, Vol. 10, Núm. 6, pp. 657-662

  2. Urine metabolome profiling of immune-mediated inflammatory diseases

    BMC Medicine, Vol. 14, Núm. 1

2015

  1. Identification of risk loci for crohn's disease phenotypes using a genome-wide association study

    Gastroenterology, Vol. 148, Núm. 4, pp. 794-805

  2. Infliximab Dose Escalation as an Effective Strategy for Managing Secondary Loss of Response in Ulcerative Colitis

    Digestive Diseases and Sciences, Vol. 60, Núm. 10, pp. 3075-3084

  3. Resources utilization and costs the year before and after starting treatment with adalimumab in Crohn's disease patients

    Inflammatory Bowel Diseases, Vol. 21, Núm. 7, pp. 1631-1640